Dr. Greg Riely, medical oncologist from MSKCC, discusses the controversial question of whether patients should continue on an oral EGFR tyrosine kinase inhibitor after progression.

Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.

Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.

Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.

Dr. Jack West, medical oncologist, reviews evidence in favor of adding Avastin (bevacizumab) to the EGFR inhibitor Tarceva (erlotinib) for patients with lung cancer that harbors an activating EGFR mutation.

The concept of maintenance therapy for advanced lung cancer has emerged over the past few years. Dr. Jack West, medical oncologist, reviews the concepts behind it and treatment options for patients.

WHAT: Acquired Resistance in Lung Cancer Patient Forum
WHEN: Saturday, Oct. 3, 2015
WHERE: Marriott Waterfront San Francisco, 1800 Old Bayshore Hwy, Burlingame, CA 94010
WHO: ALK, ROS1 & EGFR lung cancer patients and their caregivers

REGISTER HERE

A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.

Please feel free to offer comments and raise questions in our Discussion Forums.

A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.

[powerpress]

Squamous cell carcinoma patients have limited options. Data presented at ASCO 2015 showed positive patient outcomes with Gilotrif (afatinib) vs Tarceva (erlotinib), but some feel that there is little value in a treatment with only modestly better results.

[powerpress]